|  |  |  |
| --- | --- | --- |
| Supplementary Table S1. Mite antigen allergy tests performed in patients per analysis set. | | |
| **Item** | **Safety analysis set  (n = 526)** | **Effectiveness analysis set (n = 371)** |
| Mite antigen allergy test  Noa  Yes  Unknowna | 9 (1.7)  513 (97.5)  4 (0.8) | 7 (1.9)  362 (97.6)  2 (0.5) |
| Skin reaction test  Negative  Positive | 1 (0.2)  20 (3.9) | 0 (0)  15 (4.1) |
| CAP-RAST  0  1  2  3  4  5  6 | 0 (0)  8 (1.6)  37 (7.2)  79 (15.4)  101 (19.7)  71 (13.8)  103 (20.1) | 0 (0)  7 (1.9)  29 (8.0)  60 (16.6)  75 (20.7)  48 (13.3)  70 (19.3) |
| MAST-33  Class 0  Class 1  Class 2  Class 3  Class 4  Class 5  Class 6 | 0 (0)  1 (0.2)  11 (2.1)  14 (2.7)  9 (1.8)  3 (0.6)  8 (1.6) | 0 (0)  0 (0)  9 (2.5)  6 (1.7)  6 (1.7)  2 (0.6)  5 (1.4) |
| View-36  Class 0  Class 1  Class 2  Class 3  Class 4  Class 5  Class 6 | 0 (0)  1 (0.2)  8 (1.6)  10 (1.9)  11 (2.1)  11 (2.1)  7 (1.4) | 0 (0)  0 (0)  6 (1.7)  7 (1.9)  8 (2.2)  7 (1.9)  3 (0.8) |
| Data are expressed as n (%).  a Patients had been diagnosed at other hospital before entering the survey study.  CAP-RAST, ImmunoCAP Specific IgE blood test (CAP)-radioallergosorbent test (RAST); MAST-33, Multiple Antigen Simultaneous Test; View-36, Multiple (36) antigen test. | | |